Chiesi are passionately committed to our investment into research and development programmes. In 2018, we invested over €381.8 million into Research & Development, equating to €1.05 million per day and 21.6% of Chiesi Group revenues.
The number of R&D programmes is also constantly increasing and diversifying; the company focuses on its three main therapeutic areas of interest: respiratory, neonatology and special care. However, the traditional therapeutic areas of the Chiesi Group are now complemented by new areas of research, including rare diseases and biotechnology.
Please select the relevant area of interest in clinical research & development. Alternatively, if you would like to get in touch regarding a commercial opportunity, please contact our business development team on email@example.com